A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT

Objective:To determine the mechanisms of resistance of K65R mutant reverse transcriptase (RT) to the currently approved nucleoside and nucleotide RT inhibitors (NRTI). Methods:Susceptibilities of K65R mutant HIV-1 to NRTI were determined in cell culture. The Ki/Km values were measured to determine the relative binding or incorporation of the NRTI, and ATP-mediated excision of incorporated NRTI was measured to determine NRTI stability as chain terminators. Results:K65R HIV-1 had decreased susceptibility to most NRTI, but increased susceptibility to zidovudine (ZDV). Ki/Km values were increased 2- to 13-fold for K65R compared to wild-type RT for all NRTI, indicating decreased binding or incorporation. However, K65R also showed decreased excision of all NRTI compared to wild-type, indicating greater stability once incorporated. At physiological nucleotide concentrations, excision of ZDV, carbovir (the active metabolite of abacavir; ABC), stavudine (d4T), and tenofovir was further decreased, while excision of didanosine (ddI), zalcitabine (ddC), lamivudine (3TC), and emtricitabine (FTC) was unchanged. The decreased binding or incorporation of ZDV by K65R appeared counteracted by decreased excision resulting in overall increased susceptibility to ZDV in cell culture. For ABC, tenofovir, and d4T, despite having decreased excision, decreased binding or incorporation resulted in reduced susceptibilities to K65R. For ddI, ddC, 3TC, and FTC, decreased binding or incorporation by K65R appeared responsible for the decreased susceptibilities in cell culture. Conclusions:NRTI resistance in cells can consist of both altered binding or incorporation and altered excision of the NRTI. For K65R, the combination of these opposing mechanisms results in decreased susceptibility to most NRTI but increased susceptibility to ZDV.

[1]  R. Haubrich,et al.  A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575 , 2005, AIDS.

[2]  M. Wulfsohn,et al.  Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate , 2004, Journal of acquired immune deficiency syndromes.

[3]  W. Scott,et al.  Effects of Primer-Template Sequence on ATP-dependent Removal of Chain-terminating Nucleotide Analogues by HIV-1 Reverse Transcriptase* , 2004, Journal of Biological Chemistry.

[4]  R. Marquet,et al.  Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). , 2004, The international journal of biochemistry & cell biology.

[5]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[6]  S. Swaminathan,et al.  Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations , 2004, Antimicrobial Agents and Chemotherapy.

[7]  M. Wulfsohn,et al.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. , 2004, The Journal of infectious diseases.

[8]  K. White,et al.  Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations* , 2004, Journal of Biological Chemistry.

[9]  T. Traut,et al.  Physiological concentrations of purines and pyrimidines , 1994, Molecular and Cellular Biochemistry.

[10]  Michael D Miller,et al.  K65R, TAMs and tenofovir. , 2004, AIDS reviews.

[11]  B. Marchand,et al.  Site-specific Footprinting Reveals Differences in the Translocation Status of HIV-1 Reverse Transcriptase , 2003, Journal of Biological Chemistry.

[12]  B. Marchand,et al.  Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC* , 2003, Journal of Biological Chemistry.

[13]  K. Anderson,et al.  Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. , 2003, Biochemistry.

[14]  W. Heneine,et al.  A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation , 2003, Journal of Virology.

[15]  B. Larder,et al.  Effects of Dipeptide Insertions between Codons 69 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Primer Unblocking, Deoxynucleoside Triphosphate Inhibition, and DNA Chain Elongation , 2003, Journal of Virology.

[16]  B. Canard,et al.  Nucleotide Analogue Binding, Catalysis and Primer Unblocking in the Mechanisms of HIV-1 Reverse Transcriptase-Mediated Resistance to Nucleoside Analogues , 2002, Antiviral therapy.

[17]  A. D. Clark,et al.  Structures of HIV‐1 reverse transcriptase with pre‐ and post‐translocation AZTMP‐terminated DNA , 2002, The EMBO journal.

[18]  L. Naeger,et al.  Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity , 2002, Antimicrobial Agents and Chemotherapy.

[19]  E. Domingo,et al.  Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. , 2002, Journal of molecular biology.

[20]  S. Sarafianos,et al.  Nucleoside Analog Resistance Caused by Insertions in the Fingers of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involves ATP-Mediated Excision , 2002, Journal of Virology.

[21]  L. Naeger,et al.  ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2002, Antimicrobial Agents and Chemotherapy.

[22]  R. Schooley,et al.  Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.

[23]  S. Sarafianos,et al.  The M184V Mutation Reduces the Selective Excision of Zidovudine 5′-Monophosphate (AZTMP) by the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[24]  B. Canard,et al.  Mechanism-based Suppression of Dideoxynucleotide Resistance by K65R Human Immunodeficiency Virus Reverse Transcriptase Using an α-Boranophosphate Nucleoside Analogue* , 2001, The Journal of Biological Chemistry.

[25]  S. Sarafianos,et al.  Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse Transcriptase , 2001, Journal of Virology.

[26]  L. Naeger,et al.  Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out? , 2001, Current opinion in investigational drugs.

[27]  L. Naeger,et al.  Increased Drug Susceptibility of HIV-1 Reverse Transcriptase Mutants Containing M184V and Zidovudine-Associated Mutations: Analysis of Enzyme Processivity, Chain-Terminator Removal and Viral Replication , 2000, Antiviral therapy.

[28]  R. Schinazi,et al.  Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates , 2000, Antimicrobial Agents and Chemotherapy.

[29]  J. Mellors,et al.  In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine , 2000, Antimicrobial Agents and Chemotherapy.

[30]  M. Wainberg,et al.  The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis , 2000, Journal of Virology.

[31]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[32]  C Stone,et al.  Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. , 2000, The Journal of infectious diseases.

[33]  C. Katlama,et al.  HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy , 2000, AIDS.

[34]  R. Schinazi,et al.  Mechanistic studies show that (−)‐FTC‐TP is a better inhibitor of HIV‐1 reverse transcriptase than 3TC‐TP , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  A. D. Clark,et al.  Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Mian,et al.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. , 1999, Molecular cell.

[37]  S. Sarafianos,et al.  Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. , 1999, Chemistry & biology.

[38]  M. Wainberg,et al.  In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA , 1998, Antiviral therapy.

[39]  J. Cherrington,et al.  Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. , 1999, The Journal of infectious diseases.

[40]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[41]  A. So,et al.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Cherrington,et al.  Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. , 1998, Molecular pharmacology.

[43]  S. Sharma,et al.  Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. , 1997, Biochemistry.

[44]  M. Tisdale,et al.  Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89 , 1997, Antimicrobial agents and chemotherapy.

[45]  T. Merigan,et al.  Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years , 1997, Antimicrobial agents and chemotherapy.

[46]  H. Mitsuya,et al.  Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay. , 1997, Biochemistry.

[47]  C. Boucher,et al.  Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay , 1996, Antimicrobial agents and chemotherapy.

[48]  M. Wainberg,et al.  The K65R Mutation Confers Increased DNA Polymerase Processivity to HIV-1 Reverse Transcriptase* , 1996, The Journal of Biological Chemistry.

[49]  M. Wainberg,et al.  Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1 , 1996, Journal of virology.

[50]  R. Schinazi,et al.  Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases , 1996, Antimicrobial agents and chemotherapy.

[51]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[52]  M. Wainberg,et al.  The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. , 1994, The Journal of biological chemistry.

[53]  M A Wainberg,et al.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine , 1994, Antimicrobial Agents and Chemotherapy.

[54]  S. Hammer,et al.  Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group , 1994, Antimicrobial Agents and Chemotherapy.

[55]  J. Hsieh,et al.  Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. , 1993, The Journal of biological chemistry.

[56]  F. Lori,et al.  Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Wainberg,et al.  High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase , 1993, Antimicrobial Agents and Chemotherapy.

[58]  S D Kemp,et al.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Wainberg,et al.  The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine , 1993, Antimicrobial Agents and Chemotherapy.

[60]  R F Schinazi,et al.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides , 1993, Antimicrobial Agents and Chemotherapy.

[61]  K. Anderson,et al.  Mechanism and fidelity of HIV reverse transcriptase. , 1992, The Journal of biological chemistry.

[62]  S. Benkovic,et al.  Kinetic mechanism of DNA polymerase I (Klenow fragment): identification of a second conformational change and evaluation of the internal equilibrium constant. , 1991, Biochemistry.

[63]  P. Hauschka.  Chapter 19 Analysis of Nucleotide Pools in Animal Cells , 1974 .

[64]  P. Hauschka.  Analysis of nucleotide pools in animal cells. , 1973, Methods in cell biology.